Abstract 49P
Background
There is scant data on outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy in real-world, resource-constrained settings. Factors affecting outcomes in patients who achieve pathological complete response (pCR) are insufficiently explored.
Methods
This was a retrospective analysis of HER2-positive breast cancer patients treated with neoadjuvant chemotherapy (NACT) with or without HER2-targeted therapy between Jan 2014 & Dec 2018. The endpoints were pCR, event-free survival (EFS) and overall survival (OS).
Results
1004 patients were included in the analysis with a median age of 47 years, 533 (53.1%) with cT3/T4, 466 (46.4%) with cN2/3, 527 (52.5%) with ER/PR-positive tumours, 528 (52.3%) received HER2-therapy with NACT, and 711 (70.8%) received it anytime during curative treatment. The 5-year EFS in all patients was 63.5% (95%CI 60.36-66.63%) and was significantly higher with pCR vs without pCR (86.1% vs 57.0%, HR 0.282, 95%CI 0.198-0.401, p=0.000), cT1/T2 vs cT3/T4 (66.8% vs 60.6%, HR 0.767, 95%CI 0.626-0.939, p=0.01), cN0/N1 vs cN2/N3 (67.9% vs 58.5%, HR 0.772, 95%CI 0.632-0.944, p=0.01), and ever-received vs never-received HER2-therapy (69.5% vs 50.1%, HR 0.537, 95%CI 0.438-0.659, p=0.000). The 5-year OS in all patients was 69.6% (95%CI 66.66-72.54%) and was significantly higher in pCR, cT1/T2, cN0/N1, and ever-received HER2-therapy subgroups. In the pCR subgroup (n=226), there was a trend towards higher 5-year EFS among patients with cT1/T2 vs cT3/T4 (90.0% vs 82.5%, HR 0.546, 95%CI 0.270-1.103, p=0.08), cN0/N1 vs cN2/N3 (89.3% vs 82.4%, HR 0.641, 95%CI 0.326-1.262, p=0.195), and ER/PR-positive) vs ER/PR-negative tumours (90.9% vs 83.0%, HR 0.609, 95%CI 0.291-1.274, p=0.183), but there was no difference between ever-received (n=204) vs never-received (n=22) HER2-therapy (86.1% vs 86.4%, HR 0.880, 95%CI 0.309-2.504, p=0.811).
Conclusions
The receipt of HER2-targeted therapy and achievement of pCR significantly impact survival of HER2-positive breast cancer patients treated with neoadjuvant therapy. In patients who achieve pCR baseline disease burden tends to influence survival but not receipt of HER2-targeted therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract